AVR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Anteris Technologies does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. The stock is currently underperforming, with weak technical indicators, no significant recent news, and a negative financial performance trend. While analysts are optimistic about its future potential in the TAVR market, the lack of immediate positive catalysts and the current price trend suggest holding off on investment for now.
The MACD is negatively contracting below 0, indicating bearish momentum. RSI is at 27.383, which is in the neutral zone but close to oversold territory. The stock is trading near its support level (S1: 5.358), and moving averages are converging, showing no clear trend. Overall, the technical indicators suggest a weak price trend.
Analysts are optimistic about the company's DurAVR platform, which could disrupt the TAVR market upon FDA approval. Recent financing has reduced capital overhang and strengthened the company's position for future growth.
The stock has seen a consistent decline in price, with a -2.53% regular market change and bearish technical indicators. Financial performance in Q4 2025 showed a significant revenue drop (-42.18% YoY), and there is no recent news or congress trading activity to act as a positive catalyst.
In Q4 2025, revenue dropped by -42.18% YoY to $310,000. However, net income improved by 50.72% YoY to -$29.2M, and EPS increased by 37.04% YoY to -0.74. Gross margin improved to 70.65%, up 15.35% YoY. Despite some improvements, the overall financial performance remains weak.
Analysts have given the stock an Overweight rating with price targets ranging from $15 to $17. They highlight the potential of the DurAVR platform to capture market share in the TAVR market. However, recent price target reductions reflect concerns over financing and execution risks.
